SG10201802501RA - Inhibitors of lysine specific demethylase-1 - Google Patents

Inhibitors of lysine specific demethylase-1

Info

Publication number: SG10201802501RA
Authority: SG; Singapore
Prior art keywords: inhibitors; specific demethylase; lysine specific; lysine; demethylase
Prior art date: 2014-07-03

Application number

SG10201802501RA

Inventor

Young Chen

Toufike Kanouni

Zhe Nie

Jeffrey Stafford

James Veal

Original Assignee

Celgene Quanticel Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-03

Filing date

2015-06-29

Publication date

2018-05-30

2015-06-29 Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc

2018-05-30 Publication of SG10201802501RA publication Critical patent/SG10201802501RA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Polyamides (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SG10201802501RA 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1 SG10201802501RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462020886P	2014-07-03	2014-07-03

Publications (1)

Publication Number	Publication Date
SG10201802501RA true SG10201802501RA (en)	2018-05-30

Family

ID=55019883

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201802501RA SG10201802501RA (en)	2014-07-03	2015-06-29	Inhibitors of lysine specific demethylase-1
SG11201610975RA SG11201610975RA (en)	2014-07-03	2015-06-29	Inhibitors of lysine specific demethylase-1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201610975RA SG11201610975RA (en)	2014-07-03	2015-06-29	Inhibitors of lysine specific demethylase-1

Country Status (29)

Country	Link
US (3)	US9902719B2 (en)
EP (2)	EP3164380B1 (en)
JP (2)	JP6663866B2 (en)
KR (1)	KR102475498B1 (en)
CN (2)	CN106795103B (en)
AU (1)	AU2015284383B2 (en)
BR (1)	BR112017000043A2 (en)
CA (1)	CA2954049A1 (en)
CL (1)	CL2016003422A1 (en)
CO (1)	CO2017000549A2 (en)
CY (1)	CY1125127T1 (en)
DK (2)	DK3511319T3 (en)
EA (2)	EA033698B1 (en)
EC (1)	ECSP17006821A (en)
ES (2)	ES2907676T3 (en)
FI (1)	FI3511319T3 (en)
HR (2)	HRP20220414T1 (en)
HU (2)	HUE058852T2 (en)
IL (2)	IL249881B (en)
LT (2)	LT3164380T (en)
MX (2)	MX376207B (en)
PL (2)	PL3511319T3 (en)
PT (2)	PT3511319T (en)
RS (2)	RS63074B1 (en)
SA (1)	SA517380651B1 (en)
SG (2)	SG10201802501RA (en)
SI (2)	SI3164380T1 (en)
SM (2)	SMT202300205T1 (en)
WO (1)	WO2016003917A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6855466B2 (en)	2015-06-12	2021-04-07	オリゾンジェノミックスソシエダッドアノニマ	Biomarkers associated with LSD1 inhibitors and their use
WO2017013061A1 (en)	2015-07-17	2017-01-26	Oryzon Genomics, S.A.	Biomarkers associated with lsd1 inhibitors and uses thereof
SG10201913331VA (en)	2016-03-15	2020-03-30	Oryzon Genomics Sa	Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2019512546A (en)	2016-03-16	2019-05-16	オリゾン・ゲノミクス・ソシエダッド・アノニマ	Methods for determining KDM1A target association, and chemical probes useful therefor
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
WO2018083189A1 (en)	2016-11-03	2018-05-11	Oryzon Genomics, S.A.	Biomarkers for determining responsiveness to lsd1 inhibitors
FI3661510T3 (en)	2017-08-03	2024-12-18	Oryzon Genomics Sa	Methods of treating behavior alterations
LT3833670T (en) *	2018-08-10	2024-06-25	Navire Pharma, Inc.	6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
JP7532386B2 (en)	2019-02-01	2024-08-13	ハンミファーマシューティカルズカンパニーリミテッド	Imidazopyridine derivative compounds and their uses
CN113365996B (en) *	2019-02-01	2024-09-03	韩美药品株式会社	Imidazolopyridine derivative compounds and pharmaceutical compositions
WO2020188089A1 (en)	2019-03-20	2020-09-24	Oryzon Genomics, S.A.	Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
CN113613653A (en)	2019-03-20	2021-11-05	奥莱松基因组股份有限公司	Method of treating borderline personality disorder
WO2021004610A1 (en)	2019-07-05	2021-01-14	Oryzon Genomics, S.A.	Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US11360505B2 (en)	2020-02-11	2022-06-14	Simmonds Precision Products, Inc.	Distributed network time synchronization
CN114105950B (en) *	2020-08-31	2022-09-06	南京明德新药研发有限公司	Pyrazole compound and application thereof
CN117015540A (en) *	2021-03-11	2023-11-07	南京明德新药研发有限公司	Thiophene compound and application thereof
US20240216357A1 (en) *	2021-03-24	2024-07-04	Sichuan Huiyu Pharmaceutical Co., Ltd.	Polycyclic compound and application thereof
WO2022214303A1 (en)	2021-04-08	2022-10-13	Oryzon Genomics, S.A.	Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (en) *	2021-11-11	2023-05-12	中国科学院上海药物研究所	Aromatic heterocyclic compound and application thereof
EP4522137A1 (en)	2022-05-09	2025-03-19	Oryzon Genomics, S.A.	Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en)	2022-05-09	2025-03-19	Oryzon Genomics, S.A.	Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
KR20250109775A (en)	2022-11-24	2025-07-17	오리존 지노믹스 에스.에이.	Combination of LSD1 inhibitors and menin inhibitors for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1963188A1 (en)	1969-12-17	1971-06-24	Bayer Ag	New cyanophenyl-1,4-dihydropyridine derivatives
AU2002214546A1 (en) *	2000-09-29	2002-04-08	Cor Therapeutics, Inc.	Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) *	2002-04-10	2008-04-29	Bexel Pharmaceuticals Inc.	Pyrimidone derivatives
JP2005170792A (en) *	2002-11-22	2005-06-30	Mitsubishi Pharma Corp	L-proline derivatives and their pharmaceutical use.
US7504423B2 (en)	2003-12-11	2009-03-17	Mitsubishi Tanabe Pharma Corporation	α-amino acid derivatives and use thereof as medicines
WO2006073167A1 (en) *	2005-01-07	2006-07-13	Ono Pharmaceutical Co., Ltd.	Pyrrolidine derivatives
PL372332A1 (en) *	2005-01-19	2006-07-24	ADAMED Sp.z o.o.	New compounds, derivatives of 3-phenylpropionic acid
WO2006129181A2 (en) *	2005-06-03	2006-12-07	Orchid Research Laboratories Limited	Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
BRPI0615048A2 (en) *	2005-09-01	2010-03-30	Lilly Co Eli	compound, pharmaceutical composition, and use of a compound
JP2007197324A (en) *	2006-01-23	2007-08-09	Toray Ind Inc	2,4,5-substituted-1,3-azole derivative
TW200815428A (en) *	2006-08-15	2008-04-01	Wyeth Corp	Oxazolidone derivatives as PR modulators
WO2008021309A1 (en)	2006-08-15	2008-02-21	Wyeth	Imidazolidin-2-one derivatives useful as pr modulators
PE20081803A1 (en)	2007-03-09	2008-12-11	Wyeth Corp	SYNTHESIS AND CHARACTERIZATION OF THE POLYMORPHIC FORM II OF 4- (2- (4,4-DIMETHYL-2-OXOOXAZOLIDIN-3-IL) THIAZOL-4-IL) BENZONITRILE
CL2008002793A1 (en) *	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
WO2009132310A1 (en) *	2008-04-25	2009-10-29	Wisconsin Alumni Research Foundation	Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en)	2010-04-14	2013-04-18	Secretary, Department Of Health And Human Services	Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) *	2010-07-14	2012-01-19	Oregon Health & Science University	Methods of treating cancer with inhibition of lysine-specific demethylase 1
SG11201405239WA (en) *	2012-03-06	2014-09-26	Lupin Ltd	Thiazole derivatives as alpha 7 nachr modulators
DK3080100T3 (en) *	2013-12-11	2023-02-06	Celgene Quanticel Res Inc	INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE-1
CN106164071B (en) *	2014-02-14	2019-09-10	不列颠哥伦比亚大学	Human androgenic receptor DNA- binding structural domain (DBD) compound and its application method as therapeutic agent
CN106659914B (en) *	2014-05-01	2020-06-19	赛尔基因昆蒂赛尔研究公司	Inhibitors of lysine-specific demethylase-1
FR3020945B1 (en)	2014-05-16	2016-05-06	Oreal	COMPOSITION FOR COLORING KERATINIC FIBERS COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER
US10011583B2 (en) *	2014-06-27	2018-07-03	Celgene Quanticel Research, Inc.	Inhibitors of lysine specific demethylase-1
KR102450671B1 (en) *	2014-07-03	2022-10-04	셀젠 콴티셀 리서치, 인크.	Inhibitors of lysine specific demethylase-1

2015
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
- 2015-06-29 SI SI201531797T patent/SI3164380T1/en unknown
- 2015-06-29 PT PT191569763T patent/PT3511319T/en unknown
- 2015-06-29 MX MX2017000168A patent/MX376207B/en active IP Right Grant
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/en active
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/en not_active Application Discontinuation
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 RS RS20220311A patent/RS63074B1/en unknown
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 MX MX2020010900A patent/MX395534B/en unknown
- 2015-06-29 RS RS20230452A patent/RS64423B1/en unknown
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/en active Active
- 2015-06-29 ES ES15814038T patent/ES2907676T3/en active Active
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/en unknown
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en not_active Ceased
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/en not_active Expired - Fee Related
- 2015-06-29 SM SM20230205T patent/SMT202300205T1/en unknown
- 2015-06-29 SI SI201531948T patent/SI3511319T1/en unknown
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/en unknown
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/en unknown
- 2015-06-29 EA EA201790085A patent/EA033698B1/en not_active IP Right Cessation
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/en unknown
- 2015-06-29 SM SM20220136T patent/SMT202200136T1/en unknown
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/en not_active Expired - Fee Related
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/en unknown
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/en unknown
- 2015-06-29 ES ES19156976T patent/ES2948782T3/en active Active
- 2015-06-29 PL PL15814038T patent/PL3164380T3/en unknown
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/en not_active Expired - Fee Related
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/en active
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/en unknown
- 2015-06-29 EA EA201891526A patent/EA201891526A3/en unknown
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/en active
- 2015-06-29 PT PT158140384T patent/PT3164380T/en unknown
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/en unknown
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/en unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/en unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/en unknown
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/en not_active Expired - Fee Related
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
2022
- 2022-04-11 CY CY20221100269T patent/CY1125127T1/en unknown

Also Published As

Publication number	Publication date
EP3511319A1 (en)	2019-07-17
PT3511319T (en)	2023-06-29
JP6768857B2 (en)	2020-10-14
PL3511319T3 (en)	2023-09-11
CN106795103B (en)	2019-07-12
MX2020010900A (en)	2022-09-13
SG11201610975RA (en)	2017-01-27
US20170129882A1 (en)	2017-05-11
JP2019108346A (en)	2019-07-04
US20190002456A1 (en)	2019-01-03
HUE062558T2 (en)	2023-11-28
SI3511319T1 (en)	2023-10-30
IL249881B (en)	2020-01-30
EA201891526A2 (en)	2018-12-28
JP2017525668A (en)	2017-09-07
WO2016003917A1 (en)	2016-01-07
JP6663866B2 (en)	2020-03-13
CN108530424A (en)	2018-09-14
DK3164380T3 (en)	2022-03-28
CO2017000549A2 (en)	2017-04-20
IL272130B (en)	2021-03-25
US9902719B2 (en)	2018-02-27
SMT202300205T1 (en)	2023-09-06
DK3511319T3 (en)	2023-07-31
IL249881A0 (en)	2017-03-30
ES2948782T3 (en)	2023-09-19
HRP20230595T1 (en)	2023-09-15
BR112017000043A2 (en)	2018-07-17
CN108530424B (en)	2021-10-01
KR20170018100A (en)	2017-02-15
US10100046B2 (en)	2018-10-16
MX2017000168A (en)	2017-05-01
CY1125127T1 (en)	2024-02-16
MX376207B (en)	2025-03-07
EP3164380A1 (en)	2017-05-10
EA201790085A1 (en)	2017-08-31
FI3511319T3 (en)	2023-07-20
AU2015284383A1 (en)	2017-02-02
EP3164380B1 (en)	2022-02-09
RS63074B1 (en)	2022-04-29
CN106795103A (en)	2017-05-31
AU2015284383B2 (en)	2019-04-18
HRP20220414T1 (en)	2022-05-27
LT3164380T (en)	2022-06-27
RS64423B1 (en)	2023-09-29
ECSP17006821A (en)	2017-03-31
MX395534B (en)	2025-03-25
SMT202200136T1 (en)	2022-05-12
EP3511319B1 (en)	2023-05-03
PL3164380T3 (en)	2022-04-04
CL2016003422A1 (en)	2017-11-10
EA033698B1 (en)	2019-11-18
CA2954049A1 (en)	2016-01-07
US20180127408A1 (en)	2018-05-10
PT3164380T (en)	2022-03-02
KR102475498B1 (en)	2022-12-07
LT3511319T (en)	2023-08-25
IL272130A (en)	2020-03-31
HUE058852T2 (en)	2022-09-28
SA517380651B1 (en)	2020-09-30
EP3164380A4 (en)	2018-07-18
EA201891526A3 (en)	2019-05-31
ES2907676T3 (en)	2022-04-26
SI3164380T1 (en)	2022-06-30

Publication	Publication Date	Title
IL272130B (en)	2021-03-25	Inhibitors of lysine specific demethylase-1
IL250876B (en)	2021-09-30	Inhibitors of lysine specific demethylase-1
ZA201607613B (en)	2017-11-29	Inhibitors of lysine specific demethylase-1
ZA201700069B (en)	2018-04-25	Inhibitors of lysine specific demethylase-1
ZA201700072B (en)	2018-04-25	Inhibitors of lysine specific demethylase-1
PL3204352T3 (en)	2020-12-14	Inhibitors of lysine gingipain
HK1234047A1 (en)	2018-02-09	Inhibitors of lysine specific demethylase-1
HK1231134A1 (en)	2017-12-15	Inhibitors of lysine specific demethylase-1
HK1231843A1 (en)	2017-12-29	Inhibitors of lysine specific demethylase-1